Role of lipotoxicity in the development and progression of nonalcoholic fatty liver disease

Lihui ZHANG; Minghao LIU; Wenxia ZHAO

doi:10.3969/j.issn.1001-5256.2021.02.045

Volume 37 Issue 2

Mar. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(2): 463-466

PDF( 1962 KB)

Role of lipotoxicity in the development and progression of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.02.045

Department of Hepatology and Spleen-Stomach, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, China

Received Date: 2020-07-29
Accepted Date: 2020-08-17
Published Date: 2021-02-20

Abstract

Abstract

Nonalcoholic fatty liver disease (NAFLD) is currently the leading cause of abnormal liver biochemical parameters, but the mechanism of its development and progression remains unclear and there is a lack of effective treatment methods. This article reviews that lipotoxicity drives the transformation of NAFLD to nonalcoholic steatohepatitis and liver cirrhosis by triggering the three pathological responses in the liver, i.e., endoplasmic reticulum stress, cell death, and inflammation. It is believed that lipotoxicity is an important factor that promotes the progression of NAFLD to inflammation and fibrosis, which provides a new method for the prevention and treatment of NAFLD.
- Non-alcoholic Fatty Liver Disease,
- Lipotoxicity,
- Endoplasmic Reticulum Stress,
- Cell Death,
- Inflammation

FullText(HTML)

References(51)

References

[1]	DIEHL AM, DAY C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med, 2017, 377(21): 2063-2072. DOI: 10.1056/NEJMra1503519
[2]	ZHOU Q, SU J, JI MY. Progress in the treatment of nonalcoholic fatty liver disease[J]. China Med Herald, 2020, 17(6): 26-29. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202006008.htm 周谦, 苏娟, 季梦遥. 非酒精性脂肪性肝病的治疗研究进展[J]. 中国医药导报, 2020, 17(6): 26-29. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202006008.htm
[3]	SHU JR, LI JQ, LIU Q. Epidemiology of nonalcoholic fatty liver disease and related risk factors[J]. J Clin Hepatol, 2019, 35(9): 2085-2090. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.09.045 舒筠然, 李俊琪, 刘琼. 非酒精性脂肪性肝病的流行病学和危险因素分析[J]. 临床肝胆病杂志, 2019, 35(9): 2085-2090. DOI: 10.3969/j.issn.1001-5256.2019.09.045
[4]	YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431
[5]	AHMED A, WONG RJ, HARRISON SA. Nonalcoholic fatty liver disease review: Diagnosis, treatment, and outcomes[J]. Clin Gastroenterol Hepatol, 2015, 13(12): 2062-2070. DOI: 10.1016/j.cgh.2015.07.029
[6]	TILG H, MOSCHEN AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis[J]. Hepatology, 2010, 52(5): 1836-1846. DOI: 10.1002/hep.24001
[7]	SCHAFFER JE. Lipotoxicity: Many roads to cell dysfunction and cell death: Introduction to a thematic review series[J]. J Lipid Res, 2016, 57(8): 1327-1328. DOI: 10.1194/jlr.E069880
[8]	ANGULO P, KLEINER DE, DAM-LARSEN S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2015, 149(2): 389-397. DOI: 10.1053/j.gastro.2015.04.043
[9]	MUSSO G, CASSADER M, PASCHETTA E, et al. Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis[J]. Gastroenterology, 2018, 155(2): 282-302. DOI: 10.1053/j.gastro.2018.06.031
[10]	CUSI K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications[J]. Gastroenterology, 2012, 142(4): 711-725. DOI: 10.1053/j.gastro.2012.02.003
[11]	MACHADO MV, DIEHL AM. Pathogenesis of nonalcoholic steatohepatitis[J]. Gastroenterology, 2016, 150(8): 1769-1777. DOI: 10.1053/j.gastro.2016.02.066
[12]	PARTHASARATHY G, REVELO X, MALHI H. Pathogenesis of nonalcoholic steatohepatitis: An overview[J]. Hepatol Commun, 2020, 4(4): 478-492. DOI: 10.1002/hep4.1479
[13]	IBRAHIM SH, HIRSOVA P, GORES GJ. Non-alcoholic steatohepatitis pathogenesis: Sublethal hepatocyte injury as a driver of liver inflammation[J]. Gut, 2018, 67(5): 963-972. DOI: 10.1136/gutjnl-2017-315691
[14]	LEBEAUPIN C, VALLÉE D, HAZARI Y, et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease[J]. J Hepatol, 2018, 69(4): 927-947. DOI: 10.1016/j.jhep.2018.06.008
[15]	ZHANG B, LI M, ZOU Y, et al. NFκB/Orai1 facilitates endoplasmic reticulum stress by oxidative stress in the pathogenesis of non-alcoholic fatty liver disease[J]. Front Cell Dev Biol, 2019, 7: 202. DOI: 10.3389/fcell.2019.00202
[16]	YANG MT, CHEN ZJ, XIAO CX, et al. Effects of sera of rats fed with Huganqingzhi tablets on endoplasmic reticulum stress in a HepG2 cell model of nonalcoholic fatty liver disease[J]. J South Med Univ, 2018, 38(11): 1277-1287. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-DYJD201811002.htm 杨妙婷, 陈芝娟, 肖淳欣, 等. 护肝清脂片药物血清对非酒精性脂肪肝细胞模型内质网应激的影响[J]. 南方医科大学学报, 2018, 38(11): 1277-1287. https://www.cnki.com.cn/Article/CJFDTOTAL-DYJD201811002.htm
[17]	WANG L, CHEN J, NING C, et al. Endoplasmic reticulum stress related molecular mechanisms in nonalcoholic fatty liver disease (NAFLD)[J]. Curr Drug Targets, 2018, 19(9): 1087-1094. DOI: 10.2174/1389450118666180516122517
[18]	SANO R, REED JC. ER stress-induced cell death mechanisms[J]. Biochim Biophys Acta, 2013, 1833(12): 3460-3470. DOI: 10.1016/j.bbamcr.2013.06.028
[19]	WANG S, CHEN Z, LAM V, et al. IRE1α-XBP1s induces PDI expression to increase MTP activity for hepatic VLDL assembly and lipid homeostasis[J]. Cell Metab, 2012, 16(4): 473-486. DOI: 10.1016/j.cmet.2012.09.003
[20]	ZHANG K, WANG S, MALHOTRA J, et al. The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis[J]. EMBO J, 2011, 30(7): 1357-1375. DOI: 10.1038/emboj.2011.52
[21]	YE D, LI FY, LAM KS, et al. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice[J]. Gut, 2012, 61(7): 1058-1067. DOI: 10.1136/gutjnl-2011-300269
[22]	NING J, HONG T, WARD A, et al. Constitutive role for IRE1α-XBP1 signaling pathway in the insulin-mediated hepatic lipogenic program[J]. Endocrinology, 2011, 152(6): 2247-2255. DOI: 10.1210/en.2010-1036
[23]	DONNELLY N, GORMAN AM, GUPTA S, et al. The eIF2α kinases: Their structures and functions[J]. Cell Mol Life Sci, 2013, 70(19): 3493-3511. DOI: 10.1007/s00018-012-1252-6
[24]	LAKE AD, NOVAK P, HARDWICK RN, et al. The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease[J]. Toxicol Sci, 2014, 137(1): 26-35. DOI: 10.1093/toxsci/kft230
[25]	XIAO G, ZHANG T, YU S, et al. ATF4 protein deficiency protects against high fructose-induced hypertriglyceridemia in mice[J]. J Biol Chem, 2013, 288(35): 25350-25361. DOI: 10.1074/jbc.M113.470526
[26]	LI H, MENG Q, XIAO F, et al. ATF4 deficiency protects mice from high-carbohydrate-diet-induced liver steatosis[J]. Biochem J, 2011, 438(2): 283-289. DOI: 10.1042/BJ20110263
[27]	DEZWAAN-MCCABE D, SHELDON RD, GORECKI MC, et al. ER stress inhibits liver fatty acid oxidation while unmitigated stress leads to anorexia-induced lipolysis and both liver and kidney steatosis[J]. Cell Rep, 2017, 19(9): 1794-1806. DOI: 10.1016/j.celrep.2017.05.020
[28]	CHEN X, ZHANG F, GONG Q, et al. Hepatic ATF6 increases fatty acid oxidation to attenuate hepatic steatosis in mice through peroxisome proliferator-activated receptor α[J]. Diabetes, 2016, 65(7): 1904-1915. DOI: 10.2337/db15-1637
[29]	ALKHOURI N, CARTER-KENT C, FELDSTEIN AE. Apoptosis in nonalcoholic fatty liver disease: Diagnostic and therapeutic implications[J]. Expert Rev Gastroenterol Hepatol, 2011, 5(2): 201-212. DOI: 10.1586/egh.11.6
[30]	ZHANG J, ZHANG H, DENG X, et al. Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice[J]. Life Sci, 2018, 192: 46-54. DOI: 10.1016/j.lfs.2017.11.027
[31]	CAZANAVE SC, MOTT JL, BRONK SF, et al. Death receptor 5 signaling promotes hepatocyte lipoapoptosis[J]. J Biol Chem, 2011, 286(45): 39336-39348. DOI: 10.1074/jbc.M111.280420
[32]	MA ZW, LIU DX. Humanin decreases mitochondrial membrane permeability by inhibiting the membrane association and oligomerization of Bax and Bid proteins[J]. Acta Pharmacol Sin, 2018, 39(6): 1012-1021. DOI: 10.1038/aps.2017.169
[33]	CAZANAVE SC, ELMI NA, AKAZAWA Y, et al. CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis[J]. Am J Physiol Gastrointest Liver Physiol, 2010, 299(1): g236-g243. DOI: 10.1152/ajpgi.00091.2010
[34]	IURLARO R, MUÑOZ-PINEDO C. Cell death induced by endoplasmic reticulum stress[J]. FEBS J, 2016, 283(14): 2640-2652. DOI: 10.1111/febs.13598
[35]	SHEN X, LI LP. Progress in the relationship between apoptosis and nonalcoholic fatty liver disease[J]. Int J Dig Dis, 2014, 34(4): 245-248, 252. (in Chinese) DOI: 10.3969/j.issn.1673-534X.2014.04.006 沈雪, 李良平. 非酒精性脂肪性肝病与细胞凋亡关系的研究进展[J]. 国际消化病杂志, 2014, 34(4): 245-248, 252. DOI: 10.3969/j.issn.1673-534X.2014.04.006
[36]	KUBES P, MEHAL WZ. Sterile inflammation in the liver[J]. Gastroenterology, 2012, 143(5): 1158-1172. DOI: 10.1053/j.gastro.2012.09.008
[37]	HIRSOVA P, GORES GJ. Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis[J]. Cell Mol Gastroenterol Hepatol, 2015, 1(1): 17-27. DOI: 10.1016/j.jcmgh.2014.11.005
[38]	KAHRAMAN A, SCHLATTJAN M, KOCABAYOGLU P, et al. Major histocompatibility complex class I-related chains A and B (MIC A/B): A novel role in nonalcoholic steatohepatitis[J]. Hepatology, 2010, 51(1): 92-102. DOI: 10.1002/hep.23253
[39]	PAN J, OU Z, CAI C, et al. Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release[J]. Cell Immunol, 2018, 332: 111-120. DOI: 10.1016/j.cellimm.2018.08.006
[40]	REID DT, REYES JL, MCDONALD BA, et al. Kupffer cells undergo fundamental changes during the development of experimental NASH and are critical in initiating liver damage and inflammation[J]. PLoS One, 2016, 11(7): e0159524. DOI: 10.1371/journal.pone.0159524
[41]	BAECK C, WEHR A, KARLMARK KR, et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury[J]. Gut, 2012, 61(3): 416-426. DOI: 10.1136/gutjnl-2011-300304
[42]	CASTANHEIRA F, KUBES P. Neutrophils and NETs in modulating acute and chronic inflammation[J]. Blood, 2019, 133(20): 2178-2185. DOI: 10.1182/blood-2018-11-844530
[43]	van der WINDT DJ, SUD V, ZHANG H, et al. Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis[J]. Hepatology, 2018, 68(4): 1347-1360. DOI: 10.1002/hep.29914
[44]	IBUSUKI R, UTO H, ARIMA S, et al. Transgenic expression of human neutrophil peptide-1 enhances hepatic fibrosis in mice fed a choline-deficient, L-amino acid-defined diet[J]. Liver Int, 2013, 33(10): 1549-1556. DOI: 10.1111/liv.12203
[45]	GOMEZ-SANTOS L, LUKA Z, WAGNER C, et al. Inhibition of natural killer cells protects the liver against acute injury in the absence of glycine N-methyltransferase[J]. Hepatology, 2012, 56(2): 747-759. DOI: 10.1002/hep.25694
[46]	HIRSOVA P, IBRAHIM SH, KRISHNAN A, et al. Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes[J]. Gastroenterology, 2016, 150(4): 956-967. DOI: 10.1053/j.gastro.2015.12.037
[47]	POVERO D, EGUCHI A, NIESMAN IR, et al. Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells[J]. Sci Signal, 2013, 6(296): ra88. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM24106341
[48]	DENG ZB, LIU Y, LIU C, et al. Immature myeloid cells induced by a high-fat diet contribute to liver inflammation[J]. Hepatology, 2009, 50(5): 1412-1420. DOI: 10.1002/hep.23148
[49]	JIN J, LIU JX, YI M. Protective effect of berberine against hepatic lipid toxicity induced by high-fat diet in NAFLD mice and its related mechanism[J]. J Clin Exp Med, 2019, 18(11): 1124-1128. (in Chinese) DOI: 10.3969/j.issn.1671-4695.2019.11.002 金军, 刘吉祥, 易鸣. 黄连素对高脂饮食诱导非酒精性脂肪性肝病小鼠肝脂毒性的保护作用及相关机制研究[J]. 临床和实验医学杂志, 2019, 18(11): 1124-1128. DOI: 10.3969/j.issn.1671-4695.2019.11.002
[50]	IBRAHIM SH, HIRSOVA P, TOMITA K, et al. Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes[J]. Hepatology, 2016, 63(3): 731-744. DOI: 10.1002/hep.28252
[51]	KAKAZU E, MAUER AS, YIN M, et al. Hepatocytes release ceramide-enriched pro-inflammatory extracellular vesicles in an IRE1α-dependent manner[J]. J Lipid Res, 2016, 57(2): 233-245. DOI: 10.1194/jlr.M063412

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (839) PDF downloads(73)

Role of lipotoxicity in the development and progression of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.02.045

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Role of lipotoxicity in the development and progression of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.02.045

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content